ISELIN, N.J., Sept. 9 /PRNewswire-FirstCall/ -- SyntheMed, Inc. , a biomaterials company engaged in the development and commercialization of anti-adhesion products, announced today that REPEL-CV, the company's bioresorbable adhesion barrier film for the reduction of adhesions following cardiac surgery, has received approval from the Brazilian Ministry of Health for use in all patients who undergo open-heart surgery. REPEL-CV will be marketed throughout Brazil by Labcor Laboratorios Ltda., the leading manufacturer and marketer of prosthetic heart valves in Brazil. Gustavo Junqueira, Labcor's VP International Markets, stated, "We view REPEL-CV as a unique product opportunity and are enthused about the potential benefits it offers for the 48,000 patients per year who have open-heart surgery in our country."
Adhesions, or scar tissue, occur after virtually all open-heart surgical procedures, often resulting in the heart becoming attached to the sternum and other surrounding tissue surfaces. The presence of adhesions represents a prevalent and serious complication in secondary surgical procedures, increasing the length, cost and risk of the surgical procedure.
About SyntheMed, Inc.
SyntheMed, Inc. is a biomaterials company engaged in the development and commercialization of anti-adhesion products based on its proprietary bioresorbable polymer technology.
SOURCE SyntheMed, Inc.
CONTACT: Robert P. Hickey of SyntheMed, Inc., +1-732-404-1117,
Web site: http://www.synthemed.com/